Atrium Biotechnologies Inc. (TSX: ATB) today announced that it had revenues of US$306.1 million for the year ended December 31, 2006, up 52% from US$200.9 million for the corresponding previous fiscal year. Earnings before interest, taxes, depreciation and amortization (EBITDA) for fiscal 2006 were US$44.7 million, up 77% from US$25.2 million for the same period in 2005. Net earnings increased 86% to US$26.7 million for the year ended December 31, 2006, compared to US$14.3 million for the same preceding period. Fully diluted earnings per share for fiscal 2006 were up 71% to US$0.82 per share compared to US$0.48 per share for fiscal 2005.

Please refer to Atrium’s official Press Release for the complete text:

http://www.atrium-bio.com/en/investisseurs/communique.php?id=44&year=2007